Anticomplement C5 therapy with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome

Translational Research

Volumn 165, Issue 2, 2015, Pages 306-320

  Wong, Edwin K S ^a   Kavanagh, David ^a  

^a INSTITUTE OF HUMAN GENETICS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD59 ANTIGEN; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C3B RECEPTOR; COMPLEMENT FACTOR H; COMPLEMENT FACTOR I; CORTICOSTEROID; DECAY ACCELERATING FACTOR; ECULIZUMAB; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; HEMOGLOBIN; LACTATE DEHYDROGENASE; MEMBRANE COFACTOR PROTEIN; COMPLEMENT COMPONENT C5; COMPLEMENT INHIBITOR; MONOCLONAL ANTIBODY;

ANTICOAGULATION; BONE MARROW DEPRESSION; CELL POPULATION; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; DRUG INDUCED HEADACHE; DRUG SAFETY; FLOW CYTOMETRY; GENETIC ANALYSIS; GENETIC SCREENING; GERMLINE MUTATION; HAPLOTYPE; HEMATOPOIETIC STEM CELL; HEMOLYSIS; HEMOLYTIC ANEMIA; HEMOLYTIC UREMIC SYNDROME; HUMAN; INFECTION RISK; INTRAVASCULAR HEMOLYSIS; KIDNEY BIOPSY; KIDNEY BLOOD FLOW; KIDNEY FAILURE; KIDNEY FUNCTION; LOSS OF FUNCTION MUTATION; MENINGOCOCCOSIS; MOLECULAR MECHANICS; NONHUMAN; OPSONIZATION; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PATHOGENESIS; PREGNANCY; PRIORITY JOURNAL; PROGNOSIS; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOSIS; THROMBOTIC THROMBOCYTOPENIC PURPURA; UPPER RESPIRATORY TRACT INFECTION; ANIMAL; ANTAGONISTS AND INHIBITORS; ATYPICAL HEMOLYTIC UREMIC SYNDROME; CLINICAL TRIAL (TOPIC); FEMALE; GENETICS; HEMOGLOBINURIA, PAROXYSMAL; IMMUNOLOGY; MALE; MENINGOCOCCAL INFECTIONS; MOUSE; TRANSLATIONAL RESEARCH;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ATYPICAL HEMOLYTIC UREMIC SYNDROME; CLINICAL TRIALS AS TOPIC; COMPLEMENT C5; COMPLEMENT INACTIVATING AGENTS; FEMALE; HEMOGLOBINURIA, PAROXYSMAL; HUMANS; MALE; MENINGOCOCCAL INFECTIONS; MICE; PREGNANCY; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84921387621     PISSN: 19315244     EISSN: 18781810     Source Type: Journal    
DOI: 10.1016/j.trsl.2014.10.010     Document Type: Review

References (114)

1. D. Ricklin, G. Hajishengallis, K. Yang, and J.D. Lambris Complement: a key system for immune surveillance and homeostasis Nat Immunol 11 2010 785 797
2. C. Kemper, and J.P. Atkinson T-cell regulation: with complements from innate immunity Nat Rev Immunol 7 2007 9 18
3. A. Richards, D. Kavanagh, and J.P. Atkinson Inherited complement regulatory protein deficiency predisposes to human disease in acute injury and chronic inflammatory states: the examples of vascular damage in atypical hemolytic uremic syndrome and debris accumulation in age-related macular degeneration Adv Immunol 96 2007 141 177
4. M. Harboe, and T.E. Mollnes The alternative complement pathway revisited J Cell Mol Med 12 2008 1074 1084
5. R.A. Brodsky Advances in the diagnosis and therapy of paroxysmal nocturnal hemoglobinuria Blood Rev 22 2008 65 74
6. D. Kavanagh, T.H. Goodship, and A. Richards Atypical hemolytic uremic syndrome Semin Nephrol 33 2013 508 530
7. V.P. Ferreira, A.P. Herbert, and C. Cortes The binding of factor H to a complex of physiological polyanions and C3b on cells is impaired in atypical hemolytic uremic syndrome J Immunol 182 2009 7009 7018
8. E.K. Wong, H.E. Anderson, and A.P. Herbert Characterization of a factor H mutation that perturbs the alternative pathway of complement in a family with membranoproliferative GN J Am Soc Nephrol 25 2014 2425 2433
9. Y. Yu, M.P. Triebwasser, and E.K. Wong Whole-exome sequencing identifies rare, functional CFH variants in families with macular degeneration Hum Mol Genet 123 2014 5883 5893
10. D. Kavanagh, E.J. Kemp, and E. Mayland Mutations in complement factor I predispose to development of atypical hemolytic uremic syndrome J Am Soc Nephrol 16 2005 2150 2155
11. J.M. Seddon, Y. Yu, and E.C. Miller Rare variants in CFI, C3 and C9 are associated with high risk of advanced age-related macular degeneration Nat Genet 45 2013 1366 1370
12. A. Richards, M. Kathryn Liszewski, and D. Kavanagh Implications of the initial mutations in membrane cofactor protein (MCP; CD46) leading to atypical hemolytic uremic syndrome Mol Immunol 44 2007 111 122
13. C.J. Parker The pathophysiology of paroxysmal nocturnal hemoglobinuria Exp Hematol 35 2007 523 533
14. M.J. Telen, and A.M. Green The Inab phenotype: characterization of the membrane protein and complement regulatory defect Blood 74 1989 437 441
15. Y. Nevo, B. Ben-Zeev, and A. Tabib CD59 deficiency is associated with chronic hemolysis and childhood relapsing immune-mediated polyneuropathy Blood 121 2013 129 135
16. R.P. Rother, S.A. Rollins, C.F. Mojcik, R.A. Brodsky, and L. Bell Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria Nat Biotechnol 25 2007 1256 1264
17. T.C. Thomas, S.A. Rollins, and R.P. Rother Inhibition of complement activity by humanized anti-C5 antibody and single-chain Fv Mol Immunol 33 1996 1389 1401
18. S.M. Canfield, and S.L. Morrison The binding affinity of human IgG for its high affinity Fc receptor is determined by multiple amino acids in the CH2 domain and is modulated by the hinge region J Exp Med 173 1991 1483 1491
19. M.H. Tao, R.I. Smith, and S.L. Morrison Structural features of human immunoglobulin G that determine isotype-specific differences in complement activation J Exp Med 178 1993 661 667
20. Y. Wang, S.A. Rollins, J.A. Madri, and L.A. Matis Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease Proc Natl Acad Sci U S A 92 1995 8955 8959
21. Y. Wang, Q. Hu, J.A. Madri, S.A. Rollins, A. Chodera, and L.A. Matis Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5 Proc Natl Acad Sci U S A 93 1996 8563 8568
22. R.P. Rother, C.F. Mojcik, and E.W. McCroskery Inhibition of terminal complement: a novel therapeutic approach for the treatment of systemic lupus erythematosus Lupus 13 2004 328 334
23. R.I. Jain, L.W. Moreland, J.R. Caldwell, S.A. Rollins, and C.F. Mojcik A single dose, placebo controlled, double blind, phase I study of the humanized anti-C5 antibody h5G1.1 in patients with rheumatoid arthritis Arthritis Rheum 42 1999 S77
24. J. Tesser, A. Kivitz, R. Fleischmann, C.F. Mojcik, M. Bombara, and F. Burch Safety and efficacy of the humanized anti-C5 antibody h5G1.1 in patients with rheumatoid arthritis Arthritis Rheum 44 2001 S274
25. A. Hill, P. Hillmen, and S.J. Richards Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria Blood 106 2005 2559 2565
26. J.E. Figueroa, and P. Densen Infectious diseases associated with complement deficiencies Clin Microbiol Rev 4 1991 359 395
27. P. Strubing Paroxysmale haemoglobinurie Dtsch Med Wochenschr 8 1882 1 16
28. J.V. Dacie, and S.M. Lewis Paroxysmal nocturnal haemoglobinuria: clinical manifestations, haematology, and nature of the disease Ser Haematol 5 1972 3 23
29. C. Parker, M. Omine, and S. Richards Diagnosis and management of paroxysmal nocturnal hemoglobinuria Blood 106 2005 3699 3709
30. T.H. Ham, and J.H. Dingle Studies on destruction of red blood cells. II. Chronic hemolytic anemia with paroxysmal nocturnal hemoglobinuria: certain immunological aspects of the hemolytic mechanism with special reference to serum complement J Clin Invest 18 1939 657 672
31. L. Pillemer, L. Blum, I.H. Lepow, O.A. Ross, E.W. Todd, and A.C. Wardlaw The properdin system and immunity. I. Demonstration and isolation of a new serum protein, properdin, and its role in immune phenomena Science 120 1954 279 285
32. T. Kinoshita, N. Inoue, and J. Takeda Defective glycosyl phosphatidylinositol anchor synthesis and paroxysmal nocturnal hemoglobinuria Adv Immunol 60 1995 57 103
33. D.J. Araten, K. Nafa, K. Pakdeesuwan, and L. Luzzatto Clonal populations of hematopoietic cells with paroxysmal nocturnal hemoglobinuria genotype and phenotype are present in normal individuals Proc Natl Acad Sci U S A 96 1999 5209 5214
34. G.L. Mukhina, J.T. Buckley, J.P. Barber, R.J. Jones, and R.A. Brodsky Multilineage glycosylphosphatidylinositol anchor-deficient haematopoiesis in untreated aplastic anaemia Br J Haematol 115 2001 476 482
35. N. Inoue, T. Izui-Sarumaru, and Y. Murakami Molecular basis of clonal expansion of hematopoiesis in 2 patients with paroxysmal nocturnal hemoglobinuria (PNH) Blood 108 2006 4232 4236
36. R.A. Brodsky, M.S. Vala, J.P. Barber, M.E. Medof, and R.J. Jones Resistance to apoptosis caused by PIG-A gene mutations in paroxysmal nocturnal hemoglobinuria Proc Natl Acad Sci U S A 94 1997 8756 8760
37. N.S. Young Paroxysmal nocturnal hemoglobinuria and myelodysplastic syndromes: clonal expansion of PIG-A-mutant hematopoietic cells in bone marrow failure Haematologica 94 2009 3 7
38. J. Nowak, J. Wozniak, and E. Mendek-Czajkowska Potential link between MHC-self-peptide presentation and hematopoiesis; the analysis of HLA-DR expression in CD34-positive cells and self-peptide presentation repertoires of MHC molecules associated with paroxysmal nocturnal hemoglobinuria Cell Biochem Biophys 65 2013 321 333
39. W.F. Rosse Paroxysmal nocturnal hemoglobinuria - present status and future prospects West J Med 132 1980 219 228
40. A. Hill, R.J. Kelly, and P. Hillmen Thrombosis in paroxysmal nocturnal hemoglobinuria Blood 121 2013 4985 4996 quiz 5105
41. D.V. Devine, R.S. Siegel, and W.F. Rosse Interactions of the platelets in paroxysmal nocturnal hemoglobinuria with complement. Relationship to defects in the regulation of complement and to platelet survival in vivo J Clin Invest 79 1987 131 137
42. T. Wiedmer, S.E. Hall, T.L. Ortel, W.H. Kane, W.F. Rosse, and P.J. Sims Complement-induced vesiculation and exposure of membrane prothrombinase sites in platelets of paroxysmal nocturnal hemoglobinuria Blood 82 1993 1192 1196
43. R.P. Rother, L. Bell, P. Hillmen, and M.T. Gladwin The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin: a novel mechanism of human disease JAMA 293 2005 1653 1662
44. H.R. Gralnick, M. Vail, and L.P. McKeown Activated platelets in paroxysmal nocturnal haemoglobinuria Br J Haematol 91 1995 697 702
45. M. Ploug, T. Plesner, and E. Ronne The receptor for urokinase-type plasminogen activator is deficient on peripheral blood leukocytes in patients with paroxysmal nocturnal hemoglobinuria Blood 79 1992 1447 1455
46. S.A. Maroney, A.C. Cunningham, and J. Ferrel A GPI-anchored co-receptor for tissue factor pathway inhibitor controls its intracellular trafficking and cell surface expression J Thromb Haemost 4 2006 1114 1124
47. D.A. Clark, S.A. Butler, V. Braren, R.C. Hartmann, and D.E. Jenkins Jr. The kidneys in paroxysmal nocturnal hemoglobinuria Blood 57 1981 83 89
48. K.A. Nath, G.M. Vercellotti, and J.P. Grande Heme protein-induced chronic renal inflammation: suppressive effect of induced heme oxygenase-1 Kidney Int 59 2001 106 117
49. M.P. Schlaich, D. Schmitt, C. Ott, B.M. Schmidt, and R.E. Schmieder Basal nitric oxide synthase activity is a major determinant of glomerular haemodynamics in humans J Hypertens 26 2008 110 116
50. S.J. Richards, A.C. Rawstron, and P. Hillmen Application of flow cytometry to the diagnosis of paroxysmal nocturnal hemoglobinuria Cytometry 42 2000 223 233
51. P. Hillmen, S.M. Lewis, M. Bessler, L. Luzzatto, and J.V. Dacie Natural history of paroxysmal nocturnal hemoglobinuria N Engl J Med 333 1995 1253 1258
52. D.J. Araten, H.T. Thaler, and L. Luzzatto High incidence of thrombosis in African-American and Latin-American patients with paroxysmal nocturnal haemoglobinuria Thromb Haemost 93 2005 88 91
53. J. Nishimura, Y. Kanakura, and R.E. Ware Clinical course and flow cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and Japan Medicine (Baltimore) 83 2004 193 207
54. P. Hillmen, M. Elebute, and R. Kelly Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria Am J Hematol 85 2010 553 559
55. P. Hillmen, C. Hall, and J.C. Marsh Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria N Engl J Med 350 2004 552 559
56. P. Hillmen, N.S. Young, and J. Schubert The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria N Engl J Med 355 2006 1233 1243
57. R.A. Brodsky, N.S. Young, and E. Antonioli Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria Blood 111 2008 1840 1847
58. R.J. Kelly, A. Hill, and L.M. Arnold Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival Blood 117 2011 6786 6792
59. Y. Kanakura, K. Ohyashiki, and T. Shichishima Safety and efficacy of the terminal complement inhibitor eculizumab in Japanese patients with paroxysmal nocturnal hemoglobinuria: the AEGIS clinical trial Int J Hematol 93 2011 36 46
60. Y. Kanakura, K. Ohyashiki, and T. Shichishima Long-term efficacy and safety of eculizumab in Japanese patients with PNH: AEGIS trial Int J Hematol 98 2013 406 416
61. A.E. DeZern, D. Dorr, and R.A. Brodsky Predictors of hemoglobin response to eculizumab therapy in paroxysmal nocturnal hemoglobinuria Eur J Haematol 90 2013 16 24
62. U.M. Reiss, J. Schwartz, and K.M. Sakamoto Efficacy and safety of eculizumab in children and adolescents with paroxysmal nocturnal hemoglobinuria Pediatr Blood Cancer 61 2014 1544 1550
63. M. Lopez Rubio, M. Morado, and A. Gaya Paroxysmal nocturnal hemoglobinuria therapy with eculizumab: Spanish experience Med Clin (Barc) 137 2011 8 13
64. P. Hillmen, P. Muus, and A. Roth Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria Br J Haematol 162 2013 62 73
65. A. Hill, R.P. Rother, and X. Wang Effect of eculizumab on haemolysis-associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria Br J Haematol 149 2010 414 425
66. A. Hill, R.P. Rother, and P. Hillmen Improvement in the symptoms of smooth muscle dystonia during eculizumab therapy in paroxysmal nocturnal hemoglobinuria Haematologica 90 12 suppl 2005 ECR40
67. A.M. Risitano, R. Notaro, and L. Marando Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab Blood 113 2009 4094 4100
68. A. Hill, R.P. Rother, and L. Arnold Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization Haematologica 95 2010 567 573
69. T. Rondelli, A.M. Risitano, and R. Peffault de Latour Polymorphism of the complement receptor 1 gene correlates with the hematologic response to eculizumab in patients with paroxysmal nocturnal hemoglobinuria Haematologica 99 2014 262 266
70. M.A. Lindorfer, A.W. Pawluczkowycz, E.M. Peek, K. Hickman, R.P. Taylor, and C.J. Parker A novel approach to preventing the hemolysis of paroxysmal nocturnal hemoglobinuria: both complement-mediated cytolysis and C3 deposition are blocked by a monoclonal antibody specific for the alternative pathway of complement Blood 115 2010 2283 2291
71. C.Q. Schmidt, H. Bai, and Z. Lin Rational engineering of a minimized immune inhibitor with unique triple-targeting properties J Immunol 190 2013 5712 5721
72. M. Fridkis-Hareli, M. Storek, and I. Mazsaroff Design and development of TT30, a novel C3d-targeted C3/C5 convertase inhibitor for treatment of human complement alternative pathway-mediated diseases Blood 118 2011 4705 4713
73. A.M. Risitano, D. Ricklin, and Y. Huang Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria Blood 123 2014 2094 2101
74. M. Lee, S. Narayanan, E.G. McGeer, and P.L. McGeer Aurin tricarboxylic acid protects against red blood cell hemolysis in patients with paroxysmal nocturnal hemoglobinemia PLoS One 9 2014 e87316
75. England N. 2013/14 NHS Standard contract for paroxysmal nocturnal haemoglobinuria service (adults and adolescents). 2013 [cited 2014 Oct 15th]. Available at: http://www.england.nhs.uk/wp-content/uploads/2013/06/b05-parox-haem-serv.pdf.
76. D. Kavanagh, A. Richards, and J. Atkinson Complement regulatory genes and hemolytic uremic syndromes Annu Rev Med 59 2008 293 309
77. N. Besbas, D. Karpman, and D. Landau A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders Kidney Int 70 2006 423 431
78. C. Loirat, and V. Fremeaux-Bacchi Atypical hemolytic uremic syndrome Orphanet J Rare Dis 6 2011 60
79. C.Q. Schmidt, A.P. Herbert, H.G. Hocking, D. Uhrin, and P.N. Barlow Translational mini-review series on complement factor H: structural and functional correlations for factor H [Review] Clin Exp Immunol 151 2008 14 24
80. P. Warwicker, T.H. Goodship, and R.L. Donne Genetic studies into inherited and sporadic hemolytic uremic syndrome Kidney Int 53 1998 836 844
81. V. Frémeaux-Bacchi, E.C. Miller, and M.K. Liszewski Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome Blood 112 2008 4948 4952
82. E. Goicoechea de Jorge, C.L. Harris, and J. Esparza-Gordillo Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome Proc Natl Acad Sci U S A 104 2007 240 245
83. M. Jozsi, S. Strobel, and H.M. Dahse Anti factor H autoantibodies block C-terminal recognition function of factor H in hemolytic uremic syndrome Blood 110 2007 1516 1518
84. C. Blanc, L.T. Roumenina, and Y. Ashraf Overall neutralization of complement factor H by autoantibodies in the acute phase of the autoimmune form of atypical hemolytic uremic syndrome J Immunol 189 2012 3528 3537
85. D. Kavanagh, I.Y. Pappworth, and H. Anderson Factor I autoantibodies in patients with atypical hemolytic uremic syndrome: disease-associated or an epiphenomenon? Clin J Am Soc Nephrol 7 2012 417 426
86. M.C. Pickering, E.G. de Jorge, and R. Martinez-Barricarte Spontaneous hemolytic uremic syndrome triggered by complement factor H lacking surface recognition domains J Exp Med 204 2007 1249 1256
87. V. Fremeaux-Bacchi, E.J. Kemp, and J.A. Goodship The development of atypical haemolytic-uraemic syndrome is influenced by susceptibility factors in factor H and membrane cofactor protein: evidence from two independent cohorts J Med Genet 42 2005 852 856
88. J. Caprioli, M. Noris, and S. Brioschi Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome Blood 108 2006 1267 1279
89. E. Bresin, E. Rurali, and J. Caprioli Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype J Am Soc Nephrol 24 2013 475 486
90. A.L. Sellier-Leclerc, V. Fremeaux-Bacchi, and M.A. Dragon-Durey Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome J Am Soc Nephrol 18 2007 2392 2400
91. G.A. Hosler, A.M. Cusumano, and G.M. Hutchins Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome are distinct pathologic entities. A review of 56 autopsy cases Arch Pathol Lab Med 127 2003 834 839
92. V. Fremeaux-Bacchi, F. Fakhouri, and A. Garnier Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults Clin J Am Soc Nephrol 8 2013 554 562
93. M. Le Quintrec, J. Zuber, and B. Moulin Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome Am J Transplant 13 2013 663 675
94. E.G. de Jorge, P. Macor, and D. Paixao-Cavalcante The development of atypical hemolytic uremic syndrome depends on complement C5 J Am Soc Nephrol 22 2011 137 145
95. R.A. Gruppo, and R.P. Rother Eculizumab for congenital atypical hemolytic-uremic syndrome N Engl J Med 360 2009 544 546
96. J. Nurnberger, T. Philipp, and O. Witzke Eculizumab for atypical hemolytic-uremic syndrome N Engl J Med 360 2009 542 544
97. E.K. Wong, T.H. Goodship, and D. Kavanagh Complement therapy in atypical haemolytic uraemic syndrome (aHUS) Mol Immunol 56 2013 199 212
98. C.M. Legendre, C. Licht, and P. Muus Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome N Engl J Med 368 2013 2169 2181
99. Alexion. SPC soliris. 2014 [cited 2014 Oct 15th]. Available at: http://www.medicines.org.uk/emc/medicine/19966.
100. F. Fakhouri, Y. Delmas, and F. Provot Insights from the use in clinical practice of eculizumab in adult patients with atypical hemolytic uremic syndrome affecting the native kidneys: an analysis of 19 cases Am J Kidney Dis 63 2014 40 48
101. H. Povey, R. Vundru, N. Junglee, and M. Jibani Renal recovery with eculizumab in atypical hemolytic uremic syndrome following prolonged dialysis Clin Nephrol 82 2013 326 331
102. G. Ardissino, S. Testa, and I. Possenti Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases Am J Kidney Dis 64 2014 633 637
103. F. Ozaltin, B. Li, and A. Rauhauser DGKE variants cause a glomerular microangiopathy that mimics membranoproliferative GN J Am Soc Nephrol 24 2013 377 384
104. M. Lemaire, V. Fremeaux-Bacchi, and F. Schaefer Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome Nat Genet 45 2013 531 536
105. J.N. George, and C.M. Nester Syndromes of thrombotic microangiopathy N Engl J Med 371 2014 654 666
106. C. Loirat, M.A. Macher, and M. Elmaleh-Berges Non-atheromatous arterial stenoses in atypical haemolytic uraemic syndrome associated with complement dysregulation Nephrol Dial Transplant 25 2010 3421 3425
107. R. Kelly, L. Arnold, and S. Richards The management of pregnancy in paroxysmal nocturnal haemoglobinuria on long term eculizumab Br J Haematol 149 2010 446 450
108. A.V. Danilov, R.A. Brodsky, S. Craigo, H. Smith, and K.B. Miller Managing a pregnant patient with paroxysmal nocturnal hemoglobinuria in the era of eculizumab Leuk Res 34 2010 566 571
109. F. Fakhouri, L. Roumenina, and F. Provot Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations J Am Soc Nephrol 21 2010 859 867
110. G. Ardissino, M. Wally Ossola, G.M. Baffero, A. Rigotti, and M. Cugno Eculizumab for atypical hemolytic uremic syndrome in pregnancy Obstet Gynecol 122 2 Pt 2 2013 487 489
111. J. Rathbone, E. Kaltenthaler, A. Richards, P. Tappenden, A. Bessey, and A. Cantrell A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS) BMJ Open 3 2013 e003573
112. L.C. Herlitz, A.S. Bomback, and G.S. Markowitz Pathology after eculizumab in dense deposit disease and C3 GN J Am Soc Nephrol 23 2012 1229 1237
113. J. Nishimura, M. Yamamoto, and S. Hayashi Genetic variants in C5 and poor response to eculizumab N Engl J Med 370 2014 632 639
114. British national formulary: London: British Medical Association/Pharmaceutical Society of Great Britain.